These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

334 related articles for article (PubMed ID: 24490609)

  • 1. Eribulin mesylate in heavily pretreated metastatic breast cancer patients: current practice in an Italian community hospital.
    Poletti P; Ghilardi V; Livraghi L; Milesi L; Rota Caremoli E; Tondini C
    Future Oncol; 2014 Feb; 10(2):233-9. PubMed ID: 24490609
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II study of eribulin mesylate, a halichondrin B analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane.
    Vahdat LT; Pruitt B; Fabian CJ; Rivera RR; Smith DA; Tan-Chiu E; Wright J; Tan AR; Dacosta NA; Chuang E; Smith J; O'Shaughnessy J; Shuster DE; Meneses NL; Chandrawansa K; Fang F; Cole PE; Ashworth S; Blum JL
    J Clin Oncol; 2009 Jun; 27(18):2954-61. PubMed ID: 19349550
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Eribulin mesylate in advanced breast cancer: retrospective review of a single institute experience.
    Martella F; Bacci C; Giordano C; Montagnani F; Gelain E; Rabatti L; Fioretto L
    Future Oncol; 2015; 11(15 Suppl):31-6. PubMed ID: 26235263
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Feasibility and Efficacy of Eribulin Mesilate in Korean Patients with Metastatic Breast Cancer: Korean Multi-center Phase IV Clinical Study Results.
    Park YH; Kim TY; Im YH; Lee KS; Park IH; Sohn J; Lee SH; Im SA; Kim JH; Kim SH; Lee SJ; Koh SJ; Lee KH; Choi YJ; Cho EK; Lee S; Kang SY; Seo JH; Kim SB; Jung KH
    Cancer Res Treat; 2017 Apr; 49(2):423-429. PubMed ID: 27488876
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine.
    Cortes J; Vahdat L; Blum JL; Twelves C; Campone M; Roché H; Bachelot T; Awada A; Paridaens R; Goncalves A; Shuster DE; Wanders J; Fang F; Gurnani R; Richmond E; Cole PE; Ashworth S; Allison MA
    J Clin Oncol; 2010 Sep; 28(25):3922-8. PubMed ID: 20679609
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase 2 study of eribulin mesylate as first-line therapy for locally recurrent or metastatic human epidermal growth factor receptor 2-negative breast cancer.
    McIntyre K; O'Shaughnessy J; Schwartzberg L; Glück S; Berrak E; Song JX; Cox D; Vahdat LT
    Breast Cancer Res Treat; 2014 Jul; 146(2):321-8. PubMed ID: 24699910
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of eribulin monotherapy in patients with heavily pretreated metastatic breast cancer.
    Ates O; Babacan T; Kertmen N; Sarici F; Cenoli A; Akin S; Karakas Y; Kilickap S; Ozisik Y; Sever AR; Aksoy S; Altundag K
    J BUON; 2016; 21(2):375-81. PubMed ID: 27273947
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Eribulin in heavily pretreated metastatic breast cancer patients and clinical/biological feature correlations: impact on the practice.
    Fabi A; Moscetti L; Ciccarese M; Caramanti M; Salesi N; La Verde N; Russillo M; Generali D; Scandurra G; Vari S; Pacetti U; Cognetti F; Giannarelli D
    Future Oncol; 2015; 11(3):431-8. PubMed ID: 25675124
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II clinical study of eribulin monotherapy in Japanese patients with metastatic breast cancer who had well-defined taxane resistance.
    Inoue K; Saito T; Okubo K; Kimizuka K; Yamada H; Sakurai T; Ishizuna K; Hata S; Kai T; Kurosumi M
    Breast Cancer Res Treat; 2016 Jun; 157(2):295-305. PubMed ID: 27125669
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinical evaluation of eribulin mesylate for the treatment of metastatic breast cancer].
    Matsuzaki H; Tohnosu N; Yoshiwara C; Maruyama T; Tanaka H; Natsume T; Miyazaki A; Sato Y; Ohta T; Yamamoto Y; Aikawa M; Ohtsuka R; Yanagihara A; Iwata K; Shiratori T; Miyazawa Y
    Gan To Kagaku Ryoho; 2014 Apr; 41(4):455-9. PubMed ID: 24743360
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Response to eribulin in a difficult-to-treat, heavily pretreated breast cancer patient: a case report.
    Leo L; Caputo F; Sarno AD; Garofano T; Andreozzi F; Massaro MG; Montesarchio V
    Future Oncol; 2015; 11(15 Suppl):27-30. PubMed ID: 26235262
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Eribulin efficacy based on type of metastatic site: a real-life study in heavily pretreated metastatic breast cancer.
    Prestifilippo A; Grippaldi D; Blanco G; Memeo L; Puliafito I; Giuffrida D
    Future Oncol; 2017 Apr; 13(11s):5-10. PubMed ID: 28481186
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with anthracycline/taxanes.
    Chen L; Yan X; Luo T; Tian T; He P; Zhong X
    Cancer Med; 2024 May; 13(10):e7295. PubMed ID: 38785215
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Eribulin as an effective monotherapy in a chemo-pretreated woman with metastatic breast cancer: a case report.
    Caputo R; Cianniello D; De Laurentiis M
    Future Oncol; 2017 Apr; 13(11s):45-50. PubMed ID: 28481184
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term treatment with eribulin in heavily pretreated women with metastatic breast cancer: a case series.
    Morritti M; Iodice G; Melaccio A; D'Onofrio L; Bergnolo P; Boglione A; Comandone A; Molinaro P; Garigliano D
    Future Oncol; 2017 Apr; 13(11s):25-33. PubMed ID: 28481183
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Efficacy, safety and cost of eribulin in patients with metastatic breast cancer].
    Paillard MJ; Curtit E; Dobi E; Mansi L; Bazan F; Villanueva C; Chaigneau L; Montcuquet P; Meneveau N; Thiery-Vuillemin A; Nerich V; Pivot X
    Bull Cancer; 2015 Sep; 102(9):737-48. PubMed ID: 26022285
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activity of eribulin mesylate in heavily pretreated breast cancer granted access via the Cancer Drugs Fund.
    Ramaswami R; O'Cathail SM; Brindley JH; Silcocks P; Mahmoud S; Palmieri C
    Future Oncol; 2014 Feb; 10(3):363-76. PubMed ID: 24367990
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Eribulin across multiple lines of chemotherapy: a retrospective study on quality of life and efficacy in metastatic breast cancer patients.
    Quaquarini E; Sottotetti F; D'Ambrosio D; Malovini A; Morganti S; Marinello A; Pavesi L; Frascaroli M
    Future Oncol; 2017 Apr; 13(11s):11-23. PubMed ID: 28481185
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II, Multicenter, Single-arm Trial of Eribulin as First-line Therapy for Patients With Aggressive Taxane-pretreated HER2-Negative Metastatic Breast Cancer: The MERIBEL Study.
    Ortega V; Antón A; Garau I; Afonso N; Calvo L; Fernández Y; Martínez-García M; Blanco E; Zamora P; García M; Illarramendi JJ; Rodríguez Sánchez CA; Sampayo M; Aguirre E; Pérez-García JM; Cortés J; Llombart-Cussac A
    Clin Breast Cancer; 2019 Apr; 19(2):105-112. PubMed ID: 30679100
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and tolerability of eribulin mesylate in patients with pretreated metastatic breast cancer.
    Goodin S; Barbour S; Song J; Berrak E; Cox D
    Am J Health Syst Pharm; 2015 Dec; 72(24):2150-6. PubMed ID: 26637514
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.